- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
- Interventions
- MT-8421, Nivolumab
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 1,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia B
- Interventions
- REGV131, LNP1265
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2047
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- AlloStim, Cryoablation
- Biological · Procedure
- Lead sponsor
- Mirror Biologics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gilbert, Arizona
- Conditions
- Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
- Interventions
- Panzyga, 10% Intravenous Solution, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
- Interventions
- C7R-GD2.CART cells (IV and ICV infusion)
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2041
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Interventions
- Vorinostat, Niacinamide, Etoposide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dyslipidemia
- Interventions
- K-877-ER (Dose A), K-877-ER (Dose B), K-877-IR
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 9 more
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma
- Interventions
- NXP900
- Drug
- Lead sponsor
- Nuvectis Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more
- Conditions
- Hepatic Impairment
- Interventions
- AZD4144
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Mesa, Arizona • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Atrial Fibrillation
- Interventions
- HBI-3000, Placebo
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 4
- States / cities
- Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more
- Conditions
- Acute Myeloid Leukemia (AML), Cancer
- Interventions
- Venetoclax, Azacitidine, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 43
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Breast Cancer
- Interventions
- Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Leukemia, Lymphoblastic (Acute)
- Interventions
- MultiTAA-specific T cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1010, Placebo, Active Comparator
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 885 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
- Conditions
- Posterior Tibial Tendon Dysfunction
- Interventions
- Bracing, Strengthening exercises, Stretching exercises
- Device · Other
- Lead sponsor
- Ithaca College
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Advanced Solid Tumor
- Interventions
- FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2044
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Olaparib, Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- B-cell Non Hodgkin Lymphoma
- Interventions
- 1 X 10^6 cells/kg, 2.5 X 10^6 cells/kg, Dose expansion: The maximum tolerated dose of CAR-T cells
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Healthy Subjects
- Interventions
- KBP-7072, Placebo
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
- Interventions
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Biological
- Lead sponsor
- Famewave Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New Haven, Connecticut
- Conditions
- Brain Injuries, Traumatic, Spinal Cord Trauma, Intracranial Neoplasm
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Growth Disorder, Growth Hormone Deficiency in Children
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 4 Years to 13 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
- Interventions
- BGB-A445, tislelizumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania
- Conditions
- Metastatic Solid Tumors, Treatment-Refractory Cancers
- Interventions
- rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland